Inka Health selected by OneMedNet to lead AI-driven oncology project

Onco-Innovations announce that its wholly owned subsidiary, Inka Health, has been selected by OneMedNet (ONMD) Corporation to lead a high-impact data analytics initiative focused on improving how cancer therapies are brought to market. The project focuses on leveraging OneMedNet’s regulatory-grade patient data including Radiology Imaging data to develop external control arms, which has the potential to be a faster, more cost-effective alternative to traditional clinical trials. This approach offers a potentially smarter way to generate clinical evidence by leveraging existing patient data, thereby possibly accelerating treatment access and reducing the need for costly, time-consuming trials. The multi-phase project is intended to showcase how OneMedNet’s oncology dataset can be used to replicate the results of traditional clinical trials, without the same time, cost, and complexity as traditional trials. By offering a faster and more efficient path to generate the evidence needed for regulatory and reimbursement approvals, this initiative can potentially help accelerate market entry for new cancer therapies, particularly in areas of high unmet needs like colorectal cancer.